Press coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CareDx earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.7545890719648 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research analysts recently weighed in on the stock. ValuEngine upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright assumed coverage on shares of CareDx in a research report on Monday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Wednesday, January 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $8.65.
CareDx (NASDAQ CDNA) traded up $0.52 during mid-day trading on Tuesday, reaching $5.70. 211,500 shares of the company traded hands, compared to its average volume of 211,760. The company has a quick ratio of 0.35, a current ratio of 0.55 and a debt-to-equity ratio of -124.53. CareDx has a 1 year low of $0.76 and a 1 year high of $7.98. The company has a market cap of $148.17, a PE ratio of -3.15 and a beta of 0.70.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3226158/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-caredx-cdna-stock-price.html.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.